Kidney cancer, version 3.2015.


Journal Article

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.

Full Text

Cited Authors

  • Motzer, RJ; Jonasch, E; Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Chang, SS; Choueiri, TK; Costello, BA; Derweesh, IH; Gupta, S; Hancock, SL; Kim, JJ; Kuzel, TM; Lam, ET; Lau, C; Levine, EG; Lin, DW; Michaelson, MD; Olencki, T; Pili, R; Plimack, ER; Rampersaud, EN; Redman, BG; Ryan, CJ; Sheinfeld, J; Shuch, B; Sircar, K; Somer, B; Wilder, RB; Dwyer, M; Kumar, R; National comprehensive cancer network,

Published Date

  • February 2015

Published In

Volume / Issue

  • 13 / 2

Start / End Page

  • 151 - 159

PubMed ID

  • 25691606

Pubmed Central ID

  • 25691606

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0022


  • eng